Sodium-glucose cotransporter-2 inhibitors may decrease incidence of recurrent gout flares
1. Over a one-year period, the incidence of recurrent gout flares in patients with gout and diabetes was significantly lower ...
Tag: gout
#VisualAbstract: SGLT2 inhibitors reduce recurrent flares and hospitalizations in patients with gout
In this population cohort study, patients with gout who used sodium-glucose cotransporter-2 inhibitors (SGLT2is) experienced fewer recurrent flares than those ...
SGLT2 inhibitors reduce recurrent flares and hospitalizations in patients with gout
1. In this population cohort study, patients with gout who used sodium-glucose cotransporter-2 inhibitors (SGLT2is) experienced fewer recurrent flares than ...
#VisualAbstract: Changes in prescription drug and health care use over 9 years after the large drug price increase for colchicine
1. The price increase of Colchicine in the United States led to greater use of alternative medications for gout treatment, as ...
Price changes in colchicine have changed practice management for gout
1. The price increase of Colchicine in the United States led to greater use of alternative medications for gout treatment, ...
Allopurinol does not reduce cardiovascular risk for patients with ischemic heart disease without gout
1. The composite score for non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death was comparable between allopurinol (11.0%) and usual ...
Gout flares associated with a transient increase in subsequent risk of cardiovascular events
1. Amongst patients with gout, those who experienced a cardiovascular event were likely to have recently experienced a preceding gout ...
Allopurinol does not increased mortality in gout and chronic kidney disease patients
1. In patients with gout and chronic kidney disease, the initiation of allopurinol was not associated with increased mortality. 2. ...
Use of sodium-glucose transport protein 2 inhibitors associated with lowered incidence of gout in patients with type 2 diabetes
1. The use of sodium-glucose transport protein 2 inhibitors in patients with type 2 diabetes was associated with a lowered ...
Febuxostat is not associated with worse cardiovascular safety outcomes or all-cause mortality compared to allopurinol
1. Febuxostat was non-inferior to allopurinol for primary cardiovascular endpoints including hospitalization for non-fatal myocardial infarction or biomarker-positive acute coronary ...